Volume 15 Supplement 1
Immunotherapy Bridge and Melanoma Bridge 2016: meeting abstracts
Publication charges for this supplement were funded by 3P Solution, Milan, Italy. PAA has acted in a consultant/advisory role for BMS, Roche-Genentech, MSD, Novartis, Amgen, Array, Merck-Serono, Pierre-Fabre and has received research funding from BMS, Roche-Genentech, Array. RD has acted in a consultant/advisory role for Novartis, MSD, BMS, Roche, GSK, Amgen and Takeda and has received research funding from Novartis, MSD, BMS, Roche and GSK. MP has acted in a consultant/advisory role for BMS and Novartis and has received honoraria and research funding from BMS and Merck. IP, GP and MT declare that they have no competing interests.
Naples, Italy30 November - 3 December 2016
Edited by Paolo A. Ascierto, Reinhard Dummer, Giuseppe Palmieri, Michael Postow, Igor Puzanov and Magdalena Thurin.
Content type: Meeting abstracts